244.76
price down icon0.59%   -1.46
pre-market  Vorhandelsmarkt:  245.52   0.76   +0.31%
loading
Schlusskurs vom Vortag:
$246.22
Offen:
$245.81
24-Stunden-Volumen:
656.93K
Relative Volume:
0.62
Marktkapitalisierung:
$35.89B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
27.47
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
-0.42%
1M Leistung:
+4.54%
6M Leistung:
-1.83%
1J Leistung:
+18.14%
1-Tages-Spanne:
Value
$244.61
$247.00
1-Wochen-Bereich:
Value
$242.22
$247.48
52-Wochen-Spanne:
Value
$179.42
$263.05

Resmed Inc Stock (RMD) Company Profile

Name
Firmenname
Resmed Inc
Name
Telefon
(858) 746-2400
Name
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Name
Mitarbeiter
9,980
Name
Twitter
@resmed
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
RMD's Discussions on Twitter

Vergleichen Sie RMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
RMD
Resmed Inc
244.76 36.04B 5.02B 1.31B 1.56B 8.91
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
552.41 196.08B 8.71B 2.48B 1.75B 6.82
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
173.01 49.62B 20.87B 1.50B 2.59B 5.24
Medical Instruments & Supplies icon
ALC
Alcon Inc
85.38 43.30B 9.93B 1.12B 1.58B 2.25
Medical Instruments & Supplies icon
COO
The Cooper Companies, Inc.
80.12 15.87B 3.93B 415.40M 384.70M 2.06

Resmed Inc Stock (RMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-19 Eingeleitet Morgan Stanley Overweight
2025-01-16 Eingeleitet Goldman Buy
2025-01-10 Eingeleitet Piper Sandler Neutral
2024-12-13 Eingeleitet Stifel Hold
2024-09-24 Eingeleitet Robert W. Baird Outperform
2024-09-18 Herabstufung Wolfe Research Peer Perform → Underperform
2024-09-04 Herabstufung Needham Buy → Hold
2024-06-25 Herabstufung Oppenheimer Outperform → Perform
2024-06-24 Herabstufung Citigroup Buy → Neutral
2024-02-06 Fortgesetzt KeyBanc Capital Markets Overweight
2023-10-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-10-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Hochstufung JP Morgan Neutral → Overweight
2023-09-29 Herabstufung Wolfe Research Outperform → Peer Perform
2023-09-06 Hochstufung Needham Hold → Buy
2023-09-05 Herabstufung UBS Buy → Neutral
2023-08-01 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Eingeleitet UBS Buy
2023-04-14 Eingeleitet Mizuho Buy
2023-01-17 Hochstufung JP Morgan Neutral → Overweight
2022-10-28 Herabstufung Citigroup Buy → Neutral
2022-10-20 Hochstufung BofA Securities Neutral → Buy
2022-10-12 Eingeleitet Jefferies Hold
2022-09-08 Hochstufung Citigroup Neutral → Buy
2022-08-15 Herabstufung CLSA Buy → Outperform
2022-08-12 Herabstufung Citigroup Buy → Neutral
2022-08-12 Herabstufung JP Morgan Overweight → Neutral
2022-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-01-31 Hochstufung Citigroup Neutral → Buy
2022-01-31 Hochstufung Goldman Neutral → Buy
2022-01-28 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Hochstufung BofA Securities Underperform → Neutral
2022-01-24 Hochstufung JP Morgan Neutral → Overweight
2022-01-13 Hochstufung CLSA Outperform → Buy
2022-01-13 Hochstufung Robert W. Baird Neutral → Outperform
2021-12-21 Hochstufung KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Hochstufung Macquarie Neutral → Outperform
2021-10-22 Hochstufung CLSA Underperform → Outperform
2021-08-02 Herabstufung CLSA Outperform → Sell
2021-08-02 Herabstufung Needham Buy → Hold
2021-07-28 Hochstufung Jefferies Underperform → Hold
2021-07-26 Herabstufung JP Morgan Overweight → Neutral
2021-07-14 Eingeleitet RBC Capital Mkts Underperform
2021-06-28 Herabstufung Citigroup Buy → Neutral
2021-06-22 Hochstufung Macquarie Neutral → Outperform
2021-06-22 Eingeleitet Robert W. Baird Neutral
2021-06-21 Bestätigt Needham Buy
2021-06-16 Herabstufung BofA Securities Neutral → Underperform
2021-06-09 Hochstufung CLSA Sell → Outperform
2021-05-21 Hochstufung JP Morgan Neutral → Overweight
2021-05-11 Hochstufung Citigroup Neutral → Buy
2021-04-30 Herabstufung Citigroup Buy → Neutral
2021-03-16 Hochstufung Needham Hold → Buy
2020-11-02 Hochstufung UBS Neutral → Buy
2020-10-30 Hochstufung JP Morgan Underweight → Neutral
2020-10-27 Hochstufung BofA Securities Underperform → Neutral
2020-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-05-01 Herabstufung JP Morgan Neutral → Underweight
2020-05-01 Hochstufung Oppenheimer Perform → Outperform
2020-02-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-03 Eingeleitet CLSA Underperform
2020-01-31 Herabstufung UBS Buy → Neutral
2020-01-10 Eingeleitet Oppenheimer Perform
2019-11-22 Eingeleitet KeyBanc Capital Markets Sector Weight
2019-07-29 Hochstufung UBS Neutral → Buy
2019-07-16 Herabstufung UBS Buy → Neutral
2019-05-06 Hochstufung UBS Neutral → Buy
2019-04-18 Hochstufung JP Morgan Underweight → Neutral
2019-01-25 Herabstufung Goldman Buy → Neutral
2019-01-25 Herabstufung JP Morgan Neutral → Underweight
2018-10-26 Hochstufung Credit Suisse Neutral → Outperform
2018-07-02 Eingeleitet Goldman Buy
Alle ansehen

Resmed Inc Aktie (RMD) Neueste Nachrichten

pulisher
May 28, 2025

Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.

May 28, 2025
pulisher
May 27, 2025

ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks

May 27, 2025
pulisher
May 27, 2025

ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com

May 27, 2025
pulisher
May 24, 2025

ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com

May 24, 2025
pulisher
May 23, 2025

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Are Wall Street Analysts Bullish on ResMed Stock? - Inkl

May 23, 2025
pulisher
May 23, 2025

Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com

May 23, 2025
pulisher
May 23, 2025

Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

May 23, 2025
pulisher
May 22, 2025

ResMed CFO Sells Shares - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN

May 22, 2025
pulisher
May 22, 2025

Down 5%: What's going on with the ResMed share price? - MSN

May 22, 2025
pulisher
May 21, 2025

RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire

May 21, 2025
pulisher
May 21, 2025

Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Should you buy the dip in the ResMed share price? - MSN

May 21, 2025
pulisher
May 20, 2025

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India

May 20, 2025
pulisher
May 20, 2025

ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN

May 20, 2025
pulisher
May 20, 2025

Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ResMed (RMD) Faces Potential Market Challenges from New Sleep Ap - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com

May 15, 2025
pulisher
May 15, 2025

Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks

May 15, 2025
pulisher
May 15, 2025

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec

May 15, 2025
pulisher
May 15, 2025

Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance

May 15, 2025
pulisher
May 11, 2025

Resmed Inc Updates Dividend Exchange Rate for CDI Holders - TipRanks

May 11, 2025
pulisher
May 09, 2025

Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities LawsRMD - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

ResMed CEO Michael Farrell sells $1.95m in stock By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Resmed Insider Sold Shares Worth $1,948,003, According to a Recent SEC Filing - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

ResMed CEO Michael Farrell sells $1.95m in stock - Investing.com

May 09, 2025
pulisher
May 08, 2025

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech

May 07, 2025
pulisher
May 06, 2025

Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 06, 2025
pulisher
May 06, 2025

Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq

May 06, 2025
pulisher
May 05, 2025

ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks

May 05, 2025
pulisher
May 05, 2025

Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News

May 05, 2025
pulisher
May 03, 2025

Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance

May 03, 2025
pulisher
May 02, 2025

ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma

May 02, 2025
pulisher
May 02, 2025

Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive

May 02, 2025
pulisher
May 02, 2025

This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing

May 01, 2025
pulisher
May 01, 2025

ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Resmed Acquires VirtuOx - Nasdaq

May 01, 2025
pulisher
May 01, 2025

ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com

May 01, 2025

Finanzdaten der Resmed Inc-Aktie (RMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_instruments_supplies ALC
$85.38
price down icon 1.52%
medical_instruments_supplies BDX
$173.01
price down icon 0.86%
medical_instruments_supplies COO
$80.12
price down icon 0.58%
medical_instruments_supplies BAX
$30.58
price down icon 0.94%
medical_instruments_supplies WST
$211.39
price up icon 0.18%
Kapitalisierung:     |  Volumen (24h):